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Renal and systemic acid-base effects of the chronic administration of
liypercalcemia-producing agents: Calcitriol, PTH, and intravenous calci-
um. Balance studies were performed in dogs to characterize the
systemic and renal acid-base response to chronic administration of
hypercalcemia-producing agents of diverse chemical nature and mecha-
nism of calcemic action. In thyroparathyroidectomized (TVFX) dogs
(group I, N = 6), chronic oral administration of 1 ,25-dihydroxycho-
lecalciferol (I ,25-(OH)2D3; calcitriol) resulted in sustained hypercalce-
mia and chloride-resistant metabolic alkalosis. Urinary net acid excre-
tion (NAE) remained unchanged. Therefore, the increase in steady-
state plasma bicarbonate concentration was independent of the
endogenous change in the parathyroid hormone (PTH) and was in part
of extrarenal origin because NAB did not increase and in part of renal
origin because NAE did not decrease. In response to l,25-(OH)2D3
metabolic alkalosis also occurred in dogs ingesting a low Pi diet (group
2, N = 5)and in dogs that received Pi supplements (group 4, N = 6), but
in the former group there was a hypophosphaturic limitation on
titratable acid excretion and a decrease in NAE, whereas in the latter
group, there was a hyperphosphaturic accentuation of titratable acid
excretion and an increase in NAE. Significant increases in plasma
bicarbonate concentration and decreases in hydrogen ion concentration
also occurred in intact dogs administered large doses of PTH by
intermittent injection for 7 days (group 5, N = 6). In this group, as in the
TPTX dogs of group I administered I ,25-(OH)2D3, the changes in
systemic acid-base composition occurred in the absence of either
increases or decreases in NAB. Thus, chronic PTH administration as
well as I ,25-(OH)2D3 administration (group I) resulted in metabolic
alkalosis attributable to both extrarenal and renal mechanisms. Mainte-
nance of the metabolic alkalosis, however generated, is inferred to be
predominantly dependent on the renal effects of I ,25-(OH)2D3 and PTH
because without administration of these agents chronic extrarenal alkali
input to both normal and TPTX dogs did not result in metabolic
alkalosis. In TP'FX dogs with chronic hypercalcemia induced by
administration of increasing amounts of calcium in substitution for
sodium in a continuous intravenous infusion (group 8, N = 3), the
plasma bicarbonate concentration decreased and the hydrogen ion
concentration increased significantly in association with an increase in
NAE. Thus, metabolic acidosis of extrarenal origin occurred and
persisted with a directionally appropriate renal homeostatic response.
Taken together, the results of the present studies thus suggest that the
movement of calcium to or from extracellular fluid (ECF) and bone
(and/or soft tissue) in response to hypercalcemia-producing agents is
accompanied by a directionally similar movement of base equivalents
which results in either metabolic acidosis or alkalosis depending on the
direction of net movement of calcium: (1) Calcium infusion —+ base
deposition in bone/soft tissue — metabolic acidosis; (2)1 ,25-(OH)2D3 or
PTH administration — base release from bone —* metabolic alkalosis.
Moreover, chronic 1 ,25-(OH)2D3 or PTH administration increases the
set point at which the plasma bicarbonate concentration is regulated by
the kidney and thereby causes metabolic alkalosis to persist.
Effets acido-basiques renal et systemique de I'administration chronique
d'agents produisant une hypercalcemie: Calcitriol, PTH, et calcium
intraveineux. Des exp&iences de bilan ont dté rdalisées chez des chiens
pour individualiser la réponse acido-basique rénale et systémique a
l'administration chronique de divers agents produisant une hypercalcé-
mie, ces agents étant de nature chimique diverse et leur mécanisme
d'action calcémique vane. Chez des chiens thyroparathyroIdectomisés
(TPTX) (groupe 1, N = 6), l'administration chronique par voie orale de
1 ,25-dihydroxycholCcalciférol El ,25-(OH)2D3] [calcitriol] a pour consé-
quence une hypercalcémie prolongee et une alcalose metabolique
resistant au chlore. L'excrCtion uninaire nette d'acide (NAE) reste
inchangee. Par consequent l'augmentation de Ia concentration de
bicarbonate plasmatique était indépendante de Ia modification endo-
gene d'hormone parathyroidienne (PTH) et était en partie d'origine
extrarénale dans Ia mesure oO NAE n'a pas augmenté, et en partie
d'origine rénale dans Ia mesure oü NAE n'a pas diminuC. En réponse a
1 ,25-(OH)2D,, l'alcalose metabolique a aussi été observee chez des
chiens ingerant une alimentation pauvre en P1 (group 2, N = 5) et chez
des chiens recevant des supplements de Pi (group 4, N = 6). Cependant,
dans Ic groupe 2 il y avait une limitation hypophosphaturique de
l'excrétion d'acidité titrable et une diminution de NAE alors que dans le
groupe 4 ii y avait une accentuation hyperphosphatunique de l'excrétion
d'acidité titrable et une augmentation de NAE. Les augmentations
significatives de concentration de bicarbonate plasmatique et les dimi-
nutions de concentration de hydrogène ion sont aussi survenues chez
des chiens intacts recevant des doses importantes de PTH par injections
intermittentes pendant 7 jours (groupe 5, N = 6). Dans ce groupe, de
méme que chez des chiens TPTX du groupe I qui ont recu du 1,25-
(OH)2D3, les modifications de Ia composition acido-basique systemique
sont survenues en l'absence de modification de NAE. Ainsi, l'adminis-
tration chronique de PTH de même que de l,25-(OH)2D3 (groupe I) a
pour consequence une alcalose métabolique qui reléve de mécanismes a
Ia fois extrarénaux et rénaux. Le maintien de cette alcalose métabo-
lique, quel que soit son mode de génération, semble étre dependant de
facon predominante des effets rénaux du 1 ,25-(OH)2D3 et de Ia PTH
dans Ia mesure oU en l'absence de l'administration de ces agents Il n'a
pas etC observe d'alcalose métabolique au cours de l'administration
chronique d'alcalins aussi bien chez des chiens normaux que TPTX.
Chez les chiens TPTX en hypercalcemie chronique par l'administration
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de quantits croissantes de calcium par substitution pour le sodium
dans une perfusion continue (groupe 8, N = 3), concentration de
bicarbonate du plasma diminue et concentration de hydrogène ion
augmente significativement en méme temps que NAE augmente. Ainsi,
l'acidose metabolique d'origine extrarénale survient et persiste in même
temps qu'une réponse rénale homéostatique. Considérés dans leur
ensemble les résultats de ce travail suggérent que les mouvements de
calcium entre le liquide extracellulaire et l'os (et/ou les tissus mous) en
réponse aux agents qui déterminent une hypercalcémie sont accom-
pagnés par un mouvement de direction semblable de quantité équiva-
lente de base ce qui a pour résultat une alcalose metabolique ou une
acidose metabolique selon Ia direction du mouvement net de calcium:
(1) La perfusion de calcium donne une deposition de base dans l'os ou
les tissus mous, ce qui donne une acidose metabolique; (2) l'administra-
tion de 1 ,25-(OH)2D3 ou de PTH donne une liberation de base de l'os
donc une alcalose métabolique. De plus, l'administration chronique de
1,25-(OH)2D3 ou de PTH élève le point d'Cquilibre auquel concentration
de bicarbonate du plasma est regle par le rein et permet ainsi Ia
persistance de l'alcalose metabolique.
In humans and dogs acute hypercalcemia induced by intrave-
nous infusion of any of several calcium salts is associated with
an enhancement of renal acidification as evidenced by an
increased urinary net acid excretion (NAE) [1, 2] and an
increased renal bicarbonate reabsorptive capacity [3, 4]. How-
ever, it is not known whether this stimulation of renal acidifica-
tion persists when hypercalcemia is maintained chronically, or
whether the magnitude of the acid-excretory response is suffi-
cient to result in a sustained alteration in systemic acid-base
equilibrium. No characteristic abnormality of systemic acid-
base equilibrium has been described in clinical states of chronic
hypercalcemia. Metabolic acidosis and alkalosis have been
reported in association with chronic hypercalcemia [5—8], and
evidence has been provided that both disturbances of acid-base
equilibrium are sustained at least in part by renal mechanisms.
Experimental or spontaneous states of hypercalcemia are char-
acterized by numerous physiological alterations which may
have separate stimulatory or inhibitory effects on renal acidifi-
cation: alterations in circulating parathyroid hormone concen-
tration [4, 8], in vitamin D metabolism [8—12], phosphate
depletion [13, 14], and in renal hemodynamics [15], and dimin-
ished renal production of ammonia [6, 16]. The relation between
the concentration of extracellular calcium and acidification in
the mammalian kidney has not been investigated in systems
sufficiently isolated to determine whether or not calciurri direct-
ly modulates the cellular processes of renal acidification [17].
Chronic states of hypercalcemia are associated typically with
either stimulation or suppression of parathyroid hormone
(PTH) secretion. PTH has both renal and extrarenal acid-base
effects as evidenced by the results of acute hormone administra-
tion to humans and experimental animals which demonstrate
enhancement of extrarenal buffering of acid loads and inhibition
of renal net acid excretion and bicarbonate reabsorption [18—
23]. However, the chronic renal and systemic acid-base effects
of sustained administration or removal of PTH have not been
reported. Furthermore, PTH is known to modulate the rate of
renal production and plasma concentration of the potent hyper-
calcemia-producing hormone, 1 ,25-dihydroxycholecalciferol
[l,25-(OH)2D3; calcitriol], which is derived from a circulating
precursor metabolite of vitamin D, 25-hydroxycholecalciferol
[25-(OH)D3] [24]. When acutely infused into the renal artery or
systemically, 25-(OH)D3 has been demonstrated in dogs to
result in a significant increase in the renal bicarbonate reabsorp-
tive capacity [9, 10]. These findings raise the possibility that
renal acid-base effects of chronic alterations in PTH levels
might be mediated or influenced by PTH-induced alterations in
vitamin D metabolism. Whether or not vitamin D metabolites
administered chronically cause a detectable alteration in sys-
temic acid-base equilibrium has not been investigated
previously.
In our studies we developed three models in dogs of chronic
hypercalcemia induced by (1) oral administration of large
amounts of l,25-(OH)2D3, a potent metabolite of vitamin D
known to exert its calcemic effect by increasing gastrointestinal
calcium absorption and accelerating the net rate of bone demin-
eralization [24, 25], (2) intermittent injections of bovine PTH,
and (3) continuous chronic intravenous infusion of calcium. We
report the results of chronic balance studies designed to investi-
gate the systemic and renal acid-base and electrolyte responses
to hypercalcemia-producing agents in intact and thyroparathy-
roidectomized (TPTX) dogs, and in dogs in which bone demin-
eralization was inhibited by the administration of dichlorometh-
ane diphosphonate (CI2MDP).
Methods
The effects of hypercalcemia-producing agents on plasma and
urine acid-base and electrolyte composition were determined in
chronic balance studies in 36 female mongrel dogs weighing 10
to 22 kg. Throughout the studies the dogs were fed a constant
amount (30 g/kg per day) of a low electrolyte synthetic diet (4.2
mg calcium per 100 g) [26] homogenized with distilled water (60
ml/kg) and supplemented with specified amounts of sodium,
potassium, and calcium as the chloride and neutral phosphate
salts. Following the establishment of a steady-state of plasma
and urine acid-base and electrolyte composition (control peri-
od), one of several hypercalcemia-producing agents was admin-
istered each day for 3 to 24 days. Control period observations
lasted 4 to 10 days and followed a pre-feeding period of 3 to 11
days during which the dogs adjusted to the experimental diet.
Dogs that failed to eat spontaneously were tube-fed. Studies
were terminated if vomiting resulted in a cumulative loss
greater than 100 ml. Arterial blood samples were drawn from
fasted animals; they were obtained percutaneously at 9 A.M. in
heparinized glass syringes from the femoral artery at 24- to 72-
hour intervals. Urine was collected from the animals in meta-
bolic cages over stainless steel surfaces into glass bottles
containing mineral oil and a thymol-chioroform preservative.
Values for urinary excretion data are reported as normalized to
20 kg of body weight unless otherwise specified.
Group 1—Effect of 1,25-(OH)2D3 in TPTX dogs maintained
with dietary calcium carbonate (N = 7). The objective of this
protocol was to characterize the systemic and renal acid-base
response to chronic administration of 1 ,25-(OH)2D3 in the
absence of secondary changes in parathyroid gland function.
Accordingly, following a stable control period I ,25-(OH)2D3
(calcitriol capsules, Roche, Nutley, New Jersey) was adminis-
tered orally each morning to TPTX dogs for 11 days at doses of
160 ng/kg on days 1 to 3 and 80 ng/kg on days 4 to 11. A
thyroparathyroidectomy was performed at least one week prior
to control observations. The adequacy of the parathyroidecto-
my was insured by an acceptance of the animals for the study
only if the plasma total calcium concentration decreased post-
operatively by at least 2.0 mgIlOO ml. Following surgery and
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throughout the period of study, the animals were maintained on
oral levothyroxine (Armour Pharmaceuticals, Phoenix, Arizo-
na), 10 g/kg twice daily, a dosage reported to result in a
euthyroid state in dogs [27]. The electrolyte supplements to the
synthetic diet during all periods of study consisted of calcium
10.0 mEq/kg as the carbonate salt, potassium chloride 2.5
mmoles/kg and sodium chloride 2.5 mmoles/kg daily. Urinary
collections were obtained from six animals in this group.
Group 2—Effect of 1,25-(OH)2D3 in intact dogs ingesting a
low phosphorus diet to reduce the urinary phosphate buffer
excretion (N = 5). The objective of the protocol was to
investigate the effects of reduced urinary phosphate excretion
on the chronic renal and systemic acid-base response to 1,25-
(OH)2D3. Accordingly, the synthetic metabolic diet was modi-
fied by the substitution of bovine fibrin, washed ten times (U.S.
Biochemicals, Cleveland, Ohio) for casein as the dietary protein
source. Daily dietary electrolyte supplements consisted of
calcium 3.0 mEq/kg as the chloride salt, sodium chloride 3.0
and potassium chloride 3.0 mmoles/kg. Amounts of 1,25-
(OH)2D3 were administered as in group 1.
Group 3—Effect of I,25-(OH)2D3 in intact dogs ingesting a
low phosphorus diet and pretreated with dichioromethane
diphosphonate (C12MDP) (N = 4). This protocol was used to
evaluate the potential role of bone metabolism in the extrarenal
component of 1 ,25-(OH)2D3-induced metabolic alkalosis ob-
served in the phosphorus-deprived dogs of group 2. According-
ly, 1 ,25-(OH)2D3 was administered under conditions identical to
those in group 2 with the exception of pretreatment with a
potent inhibitor of bone demineralization, C12MDP (Proctor and
Gamble, Cincinnati, Ohio) 10 mg/kg, subcutaneously as a single
daily dose (10 mg/mI, pH 7.4) throughout prefeeding and control
periods [28]. Following a stable control period, 1 ,25-(OH)2D3
was administered orally as in group 2 for an 11-day period
during which C12MDP administration was continued.
Group 4—Effect of 1,25-(OH)2D3 in intact dogs ingesting a
high phosphorus diet (N = 6). We used this protocol to charac-
terize the systemic and renal acid-base and electrolyte response
to chronic administration of 1 ,25-(OH)2D3 in phosphate-replete
dogs. The daily electrolyte supplements to the diet consisted of
calcium 3.0 mEq/kg as the chloride salt, and potassium and
sodium 3.0 mEq/kg each as the neutral phosphate salts (pH 7.4).
Amounts of 1 ,25-(OH)2D3 were administered as in groups 1
and 2.
Group 5—Effect of bovine (b) PTH in intact dogs (N = 6).
The objective of this protocol was to characterize the systemic
and renal acid-base response to an additional chronic hypercal-
cemia-producing agent, PTH. Accordingly, following a stable
control period, bPTH extract, 10 to 15 USP U/kg (Eli Lilly,
Indianapolis, Indiana) was administered daily by subcutaneous
injection in 2 or 3 divided doses. The synthetic diet was
identical to that utilized in groups 1 and 4. As in group 4 the
daily electrolyte supplement to the diet consisted of calcium 3.0
mEq/kg as the chloride salt and potassium and sodium 3.0
mEq/kg each as the neutral phosphate salts.
Group 6—Effect of bPTH in intact dogs pretreated with
CI2MDP, a potent inhibitor of bone demineralization (N =3).
We used this protocol to investigate the effects of bPTH
administration in a physiological setting in which the bone
demineralization and calcemic effects of PTH are inhibited
greatly [28]. Accordingly, three dogs were administered bPTH
under identical conditions as in group 5 with the exception of
pretreatment with CI2MDP 10 mg/kg, subcutaneously as a
single daily dose. Following a stable control period, bPTH 14
U/kg was administered subcutaneously in 2 or 4 divided doses
for 9 days.
Group 7—Effect of chronic administration of sodium bicar-
bonate in intact dogs (N = 4). This protocol objective was to
investigate the renal and systemic acid-base effects of a chronic
extrarenal alkali load. Accordingly, prefeeding and control
period observations were undertaken during ingestion of the
synthetic diet supplemented with sodium chloride 5.0 mmoles/kg
and potassium 2.5 mEq/kg daily as the neutral phosphate (pH
7.4). Following a stable control period, sodium bicarbonate 2.5
mmoles/kg was substituted for an equimolar amount of sodium
chloride in the diet for a 10-day period. Following the establish-
ment of steady-state conditions during the sodium bicarbonate
administration, the animals were returned to control period
conditions for a 6-day recovery period. The synthetic diet was
supplemented with calcium 670 mg/kg diet as the neutral
phosphate (pH 7.4).
Group 8—Effect of chronic hypercalcemia induced by the
substitution of continuous intravenously administered calcium
chloride for equivalent sodium chloride to TPTX dogs (N
= 3). With this group we desired to characterize the renal and
systemic acid-base effects of prolonged hypercalcemia under
conditions in which endogenous or exogenous variation in PTH
levels and pharmacological doses of vitamin D metabolites were
not present. Accordingly, TPTX dogs were fitted with chronic
indwelling external jugular vein catheters for chronic, continu-
ous infusion of electrolytes as previously reported [29]. Follow-
ing catheter placement, an infusion of calcium 0.5 to 1.0 mEq/kg
per day as the chloride salt and sodium chloride 5.0 to 5.5
mmoles/kg per day was initiated to assure a normal or subnor-
mal steady-state plasma total calcium concentration in a stable
control period. Following a 2-day prefeeding period and a 4-day
control period, hypercalcemia was induced by increasing the
rate of calcium chloride infusion and decreasing the rate of
sodium chloride infusion for a 3 to 24-day period. In one dog the
desired calcemic response required an increase in the calcium
content of the intravenous infusion during the hypercalcemia
period to levels greater than the corresponding sodium content
in the control period. The synthetic diet was identical to that in
groups 1 and 4—6 and was supplemented with potassium 2.0
mEq/kg as the neutral phosphate and sodium bicarbonate 2.0
mmoles/kg per day. Thyroxine replacement consisted of oral
levothyroxine, 10 pg/kg twice daily. Infectious complications of
chronic intravascular catheterization were prevented by oral
administration of trimethoprim (80 mg) and sulfamethoxazole
(400 mg; Burroughs Wellcome, Research Triangle Park, North
Carolina) twice daily.
Group 9—Effect of chronic hypercalcemia induced by the
substitution of continuous intravenously administered CaS2O3
for equivalent Na2S2O3 to a TPTX dog (N = 1). This protocol
was intended to characterize the renal and systemic acid-base
effects of prolonged hypercalcemia induced by a chronic intra-
venous infusion of a non-chloride calcium salt, CaS2O3 (City
Chemical Corp., New York), to consider the possibility that the
metabolic acidosis observed in calcium-infused TPTX dogs of
group 8 was related to chloride infusion rather than to hypercal-
cemia. Like chloride, thiosulfate does not associate hydrogen
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Fig 1. Effect of I,25-(OH)2D3 on plasma
and urinary acid-base and electrolyte
composition in TPTX dogs ingesting a
high calcium diet (group 1, N = 7). NAE
represents urinary net acid excretion; P1,
inorganic phosphate; and TA, titratable
acid excretion.
ions over the range of physiologic pH (5.0 to 8.0) inasmuch as
the PKa values for H2S203 and HS2O are 0.6 and 1.6, respec-
tively [30]. Thyroparathyroidectomy, catheter placement, and
prefeeding were carried out as in group 8. Accordingly, a stable
control period lasting 4 days was obtained during which an
infusion of the thiosulfate salts of calcium (1.0 mEq/kg per day)
and sodium (5.0 mEq/kg per day) was carried out to effect a
steady-state plasma calcium concentration. Chronic hypercal-
cemia was then induced by increasing the infusion ratio of
calcium/sodium thiosulfate while maintaining a constant rate of
thiosulfate infusion for a period of 7 days. The daily dietary
electrolyte supplement consisted of sodium chloride 2.0
mmoles/kg, sodium bicarbonate 4.0 mmoles/kg, and potassium 2.0
mEq/kg as the neutral phosphate. Oral levothyroxine and antibiot-
ic treatments were identical to those in group 8.
Analytical procedures. All determinations were performed in
duplicate. Analytical methods used in our laboratory have been
tiescribed in previous reports [26, 29]. Urine and plasma total
calcium concentrations were determined by atomic absorption
spectrophotometry [31, 321 or automated fluorometric titration
[33]. The ionized calcium concentration was determined with
either an Orion model 88-20 or SS-20 ionized calcium analyzer
(Orion, Cambridge, Massachusetts) on serum collected in plas-
tic tubes. Values were corrected to simultaneously measured
arterial pH by the method of Wybenga, Ibbott, and Cannon
[34]. Net acid excretion was calculated as the sum of urinary
ammonium and titratable acidity minus bicarbonate. Anion gap
was calculated as (sodium + potassium) — (chloride + bicar-
bonate) in plasma and as (ammonium + sodium + potassium +
calcium) — (chloride + bicarbonate + monobasic phosphate +
dibasic phosphate) in urine. Statistical significance was deter-
mined by Student's t test [35].
Results
Group 1—Effect of 1,25-(OH)2D3 in TPTX dogs maintained
with dietary calcium carbonate. Prior to 1 ,25-(OH)2D3 adminis-
tration, the net acid excretion was substantially lower in the
aparathyroid dogs of this group than in groups 2—4, possibly as a
result of the large amount of potentially absorbable alkali
ingested as calcium carbonate (Fig. 1, Tables 1 and 2). Follow-
ing 1 ,25-(OH)2D3 administration, hypercalcemia and metabolic
alkalosis occurred. Net acid excretion remained essentially
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constant by virtue of a significant increase in titratable acid
excretion associated with a commensurate and significant de-
crease in ammonium excretion. Urine pH decreased significant-
ly. The increase in titratable acid excretion was due in part to an
increase in phosphate excretion.
Group 2—Effect of 1,25-(OH)2D3 in intact dogs ingesting a
low phosphorus diet to reduce the urinary phosphate buffer
excretion. Prior to 1 ,25-(OH)2D3 administration, the urinary
phosphate excretion was reduced greatly to 1.2 0.2 mmoles
per 24 hours (Table 2). Net acid excretion decreased significant-
ly during 1 ,25-(OH)2D3 administration and remained persistent-
ly decreased as the plasma bicarbonate concentration increased
significantly. Both urine ammonium excretion and pH de-
creased significantly. Plasma calcium concentration increased
as in group 1.
Group 3—Effect of 1,25-(OH)2D3 in intact dogs ingesting a
low phosphorus diet and pretreated with C12MDP. Urinary
phosphate excretion was reduced prior to 1 ,25-(OH)2D3 admin-
istration as noted in group 2. Control values of plasma bicarbon-
ate and calcium concentrations were nearly identical to those of
group 2. Following l,25-(OH)2D3 administration, metabolic
alkalosis occurred and persisted in the CI2MDP-pretreated dogs
of group 3, but the magnitude of the increase in plasma
bicarbonate concentration was less than that observed in group
2 (+2.5 0.6 versus +4.3 0.5 mEq/liter, group 3 versus 2,
Table 1). In contrast to the significant hypercalcemia that
occurred in the phosphorus-deprived dogs of group 2, pretreat-
ment with CI2MDP prevented the development of significant
hypercalcemia in group 3.
As in group 2, 1 ,25-(OH)2D3 administration resulted in a
significant reduction in net acid excretion relative to control
values (Table 2). However, the cumulative decrease in urinary
net acid excretion was significantly less in comparison with
group 2 dogs (—102 versus —222 mEq, groups 3 versus 2, day
11, P < 0.05).
Group 4—Effect of l,25-(OH)2D3 in intact dogs ingesting a
high phosphorus diet. Chronic administration of large amounts
of l,2540H)2D3 to dogs ingesting a high phosphorus diet
resulted in significant increases in plasma calcium and bicar-
bonate concentrations (Table 1). The plasma hydrogen ion
concentration decreased significantly, resulting in steady-state
metabolic alkalosis. The development of metabolic alkalosis
was associated with a significant reduction in urine pH and a
significant increase in net acid excretion (Table 2). A significant
cumulative change in urinary chloride excretion was not ob-
served (Table 2). The increase in net acid excretion was
accounted for entirely by the magnitude of the increase in
titratable acid excretion, which was due in part to a significant
cumulative increase in inorganic phosphate excretion. Both
urine pH and ammonium excretion decreased significantly.
Group 5—Effect of bPTH in intact dogs. Following PTH
administration, hypercalcemia and a sustained increase in plas-
ma bicarbonate concentration occurred in association with the
development of hyperphosphatemia and decreased renal phos-
phate clearance (Fig. 1, Table 2). Mean plasma creatinine was
not altered significantly by PTH administration. Urine pH,
titratable acid, ammonium and net acid excretion rates were not
significantly altered. No phosphaturic response to PTH oc-
curred (Fig. 2, Table 2).
Group 6—Effect of bPTH in intact dogs pretreated with
CI2MDP, a potent inhibitor of bone demineralization. Pretreat-
ment with C12MDP resulted in no significant differences from
control observations in group 5 in plasma acid-base and electro-
lyte composition other than an increase in plasma phosphorus
concentration and decreased renal phosphate clearance as
previously reported [36]. Following bPTH administration, hy-
percalcemia was prevented (z total [calcium] +0.8 0.5
mg/lOO ml, days 4 to 6; —0.2 0.5 mgIlOO ml, day 9), and no
significant change in plasma acid-base and electrolyte composi-
tion was observed (z[bicarbonate ion], —0.2 0.9 mEq/liter,
days 4 to 6; +0.8 0.6 mEq/liter, day 9).
Group 7—Effect of chronic administration of sodium bicar-
bonate in intact dogs. Chronic administration of a large dose of
sodium bicarbonate resulted in no significant alteration in
plasma acid-base composition (control versus days 7 to 10 of
sodium bicarbonate): [bicarbonate] 21.2 0.6 versus 22.4 0.5
mEq/liter; PaCO2 34.4 1.2 versus 36.1 1.8 mm Hg;
[hydrogen] 40 1 versus 39 1 nEq/liter. Daily values of
plasma and urinary acid-base composition are summarized in
Figure 3. The mean plasma potassium concentration increased
significantly from a control value of 3,5 0.1 to 3.7 0.1
mEq/liter(P < 0.001) on days 7 to 10 of the sodium bicarbonate
administration.
Group 8—Effect of chronic hypercalcemia induced by the
substitution of continuous intravenously administered calcium
chloride for equivalent sodium chloride to TPTX dogs. The
chronic administration of increasing amounts of intravenous
calcium resulted in a significant decrease in the plasma bicar-
bonate concentration and an increase in the blood hydrogen ion
concentration concomitant with the development of sustained
hypercalcemia (Fig. 4, Table 3). Because carbon dioxide ten-
sion did not decrease in response to the occurrence of metabolic
acidosis, it is necessary to postulate the coexistence of a second
primary acid-base disorder: Chronic respiratory acidosis. Urine
pH decreased significantly as net acid excretion increased
significantly.
Whereas the decrease in plasma bicarbonate concentration
depicted in Table 3 was associated with a more severe hypercal-
cemia than in groups 1 to 3, there were periods of comparable
hypercalcemia in group 8. Using all data points in the range of
plasma calcium concentration from 13 to 16 mg/lOO ml up to and
including the period of "peak hypercalcemia" (Table 3), the
mean plasma bicarbonate concentration in groups 1, 2, and 4
[1 ,25-(OH)2D3 administration] was significantly greater than
that in group 8 (i.v. calcium administration): 23.8 0.2 versus
17.5 0.6 mEq/liter, P < 0.001; mean blood [hydrogeni was
significantly lower in groups 1, 2, and 4; 39 1 versus 44 1
nEq/liter, P < 0.001. The mean plasma calcium concentration
(14.3 0.1 versus 14.7 0.2 mg/lOO ml) was not significantly
different. Thus the chronic systemic acid-base effects of similar
degrees of hypercalcemia are dissimilar for the two methods of
producing chronic hypercalcemia.
Group 9—Effect of chronic hypercalcemia induced by substi-
tution of continuous intravenously administered CaS2O3 for
equivalent Na2S2O3 to a TPTX dog. The chronic administration
of increasing amounts of intravenous calcium in the absence of
coadministration of the chloride ion resulted in sustained hyper-
calcemia and metabolic acidosis of similar magnitude as ob-
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Table 1. Effect of chronic administration of I ,25-(OH)2D3 and PTH on plasma acid-base and electrolyte composition in intact and TPTX dogs
served in group 8 dogs (Fig. 5). Changes in urine pH and net
acid excretion were indistinguishable from those in group 8.
Discussion
The results of the present studies indicate that the experimen-
tal development of chronic hypercalcemia has significant effects
on renal and extrarenal acid-base homeostasis, When chronic
hypercalcemia was generated with agents that are known to
result in the dissolution of bone salts (1 ,25-(OH)2D3 and PTH)
[25, 371, persisting increases in plasma bicarbonate concentra-
tion and decreases in blood acidity occurred indicative of
metabolic alkalosis (groups 1 to 5). Both extrarenal and renal
mechanisms appeared to contribute to the generation and/or
maintenance of this acid-base disorder.
In the TPTX dogs of group 1, 1 ,25-(OH)2D3 administration
caused a persisting increase in plasma bicarbonate concentra-
tion in the absence of significant changes in net acid excretion.
Thus, generation of metabolic alkalosis in this group must be
attributed predominantly to an extrarenal input of alkali into the
ECF compartment, for example, increased gastrointestinal al-
kali absorption and dissolution of alkali salts in bone. However,
an extrarenal mechanism cannot explain the persistence of
metabolic alkalosis in the steady-state (days 7 to 11) because net
acid excretion in the steady-state was unchanged from control.
If extrarenal alkali input to the ECF had persisted in the steady-
state, net acid excretion would be expected to be reduced from
control [38, 391. A persisting increase in base input to ECF in
the absence of a corresponding reduction in net acid excretion
would have compelled a progressive increase in plasma bicar-
bonate concentration. However, plasma bicarbonate concen-
tration was stable. The persistence of metabolic alkalosis
without reduction in net acid excretion suggests a persisting
stimulation of renal acidification resulting in an increase in the
set point at which the plasma bicarbonate concentration is
regulated by the kidney.'
Although net acid excretion was not reduced from control,
'Whereas slight hypokalemia and a kaliuresis were observed in group
1 animals, it is unlikely that hypokalemia played a major role in the
generation or maintenance of metabolic alkalosis in response to I ,25-
(OH)2D3 or PTH because alterations in potassium homeostasis were not
a constant finding (groups 1 to 5). In fact, a significant increase in the
plasma potassium concentration accompanied the observed significant
increase in plasma bicarbonate concentration in group 3. Moreover,
potassium depletion in dogs has been reported to result in renal acidosis
[401.
Period
H
nEqiliter
PaCO2
mm Hg
Anion
HCO zHCO3 gap
Group I (N = 7) TPTX, high Ca diet: Ca 10 mEq/kg as COr, KCI2.5 and NaCI 2.5 mmoles/kg daily
Control 41 34.5 20.2 15.0
Cl-
mEqiliter
Na
38.4c
3.0 mEqlkg as
36.1
l,25-(OH)2D3, 80 ng/kg p.o. daily
Days7toll 39b
Group 2 (N = 5) intact, P-restricted diet: Ca
Control 47
1,25-(OH)2D3, 80 ng/kg p.o. daily
Days7toll 40c
Group 3 (N = 4) intact, CI2MDP pretreatment,
Control 43
1,25-(OH)2D3, 80 ng/kg p.o. daily
Days7toll 40"
24.Od +3.8" 12.1"
±0.4
Cl, KCI 3.0 and NaCI 3.0 mmoles/kg daily
18.7 14.1
14.737.9"
P-restricted
33.7
23.0 43c
±0.5
diet: Ca 3.0 mEqlkg as C1,
19.2
KC1 3.0 and NaCl 3.0
14.3
1.2
113.4
111.8
115.2
110.6"
mmoles/kg daily
116.1
111 .2
115.0
113.6
114.5
115.1
115.0
35.4 21.6" +2.5" 16.0
Group 4 (N = 6) intact, P-supplemented diet: Ca 3.0 mEq/kg as C1, Na 3.0 and K 3.0 mEq/kg as P1 daily
Control 41 34.2 20.6 13.5
1,25-(OH)2D3, 80 ng/kg p.o. daily
Days 7 to 11 39' 36.3" 23.0 +2.4 12.5
Group 5 (N = 6) intact, P-supplemented diet: Ca 3.0 mEq/kg as C1, Na 3.0 and K 3.0 mEqlkg as P6 daily
Control 42 36.1 20.7 14.2
bPTH, 10 to 15 U/kg daily in 2 or 3 subcutaneous doses
High Ca' day 4lb 38.8 23.2b +2.5b 10.6c
Days4to7 4l 37.0 22.2" +1.5b 12.0"
144.7
144.2
144.6
144.6
146.2
145.2
145.5
145.5
145.7
145.2
145.5
a 1,25-(OH)2D3 dosage was 160 ng/kg daily during days Ito 3 in groups ito 4. High Ca day is defined as the first day of PTH administration in
which plasma total [Ca] was at least 12.5 mg/iOO ml. Values are means saM; mean values were tested for significant differences from control
and are footnoted by b, and"indicative of significance at the 0.05, 0.01 and 0.001 probability levels, respectively (Student's t test).
Abbreviations used are defined: H, hydrogen ion activity and PaCO2, CO2 tension in arterial blood.
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Table 1. (continued).
K
mEqiliter
Total
Ca°
1onizedCa P Protein
g/100 ml
Creatinine
mg/lOU ml
Weight
kg
C.
mi/mmmg/lOO ml
3.9 9.5 5.2 6.9 0.71 19.3 1.7
14.7 +1.8° 4.4 7.4 0.94 l8.lc 6.2b
3.4 10.5 6.1 6.8 0.81 13.9 0.3
3.8 13.4° +1.3b 5.7 6.6 0.85 13.5° 1.2
3.3 10.1 3.6 6.7 0.82 20.0 0.2
3.6b 11.3 3.3 7.0' 0.85 20.0 0.2
3.6 9.6 4.0 6.6 0.71 17.4 36.6
3.7 11.2° +0.8b 3.8 6.7 0.71 16.8" 39.4
3.7 10.2 3.8 6.5 0.71 18.7 37.9
3.7
3.6
14.1
11.5°
4.4
5.2°
6.7
6.7"
0.79
0.80
18.4b
18.5 28.Ob
urinary ammonium excretion was significantly reduced from
control and titratable acid excretion was commensurately in-
creased. The reduction in urinary ammonium excretion was
associated with a significant reduction in urine pH, a finding
which suggests a reduction in availability of renal cellular
ammonia for diffusion into tubular fluid [26, 41, 42]. This
possibility is consistent with the finding in vitro that renal
ammoniagenesis is suppressed significantly by elevation of
calcium concentration in the incubation medium [161.
The effect of l,25-(OH)2D3 administration to decrease renal
cellular availability of ammonia for urinary excretion in group 1
raises the possibility that a decrease in net acid excretion might
occur during 1 ,25-(OH)2D3 administration under conditions in
which the contribution of nonammonia buffers to net acid
excretion is restricted greatly by virtue of hypophosphaturia.
To investigate this possibility we administered 1 ,25-(OH)2D3 to
dogs with a marked degree of dietary phosphorus restriction
(group 2). In the control period urine phosphate and titratable
acid excretion were negligible, and urine ammonium excretion
accounted for 100% of the net acid excretion. In response to
1 ,25-(OH)2D3 administration, both ammonium and net acid
excretion decreased significantly in association with a signifi-
cant increase in the plasma calcium concentration, but the
plasma bicarbonate concentration increased to supernormal
levels rather than decreased. In the steady-state of chronic
hyperbicarbonatemia, net acid excretion remained significantly
decreased from control, a physiological circumstance similar to
that in which hyperbicarbonatemia might result from chronic
administration of alkali salts. These findings establish the
existence of an extrarenal alkali-generating and alkalosis-main-
taming effect of l,25-(OH)2D3 administration.
The possibility was considered whether or not the magnitude
of the steady-state increase in extrarenal input of alkali to ECF
observed in the phosphorus-restricted dogs of group 2 was
sufficient to result in the observed increment in the steady-state
plasma bicarbonate concentration. The results of chronic ad-
ministration of sufficient sodium bicarbonate (2.5 mmoles/kg
daily) to group 7 dogs to result in an even greater reduction in
steady-state net systemic acid load, provide strong evidence
against a major role for increased alkali loads in the mainte-
nance of metabolic alkalosis in the present studies. Despite
greater alkali-induced reductions in net acid excretion than in
group 2, no appreciable steady-state increase in plasma bicar-
bonate concentration was detected in group 7 dogs (Fig. 3) as
previously reported in similarly studied human subjects [38,
39].
We considered the possibility that the extrarenal alkali-
generating effect of 1 ,25-(OH)2D3 administration reflected a
reduction in the steady-state rate of endogenous production of
hydrogen ion as the fixed acids of metabolism, for example,
sulfuric and organic acids. This possibility is unlikely based on
an assessment of the effect of 1 ,25-(OH)2D3 administration on
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Table 2. Effect of chronic administration of 1 ,25-(OH)2D3 and PTH on daily and cumulative urinary acid-base and electrolyte excretion in intact
and TPTX dogsa
Net Anion
NH TA HCO acid Na K Cl Ca gap
Urine mEq/24 hrs mmoles/24 hrs mEq/24 hrs Volume
Period pH (mEq) (mmoles) (mEq) ml/24 hrs
Group I (N = 7), TPTX, High Ca diet: Ca 10 mEq/kg as COT, KCI 2.5 and NaC! 2.5mmoles/kg daily
Control 6.38 40.0 2.1 5.4 36.6 3.9 42.3 46.7 92.4 3.7 29.1 847
±0.06 ±1.0 ±0.3 ±0.9 ±1.5 ±0.6 ±1.8 ±1.2 ±2.6 ±1.3 ±2.3 ±40
1,25-(OH)2D3, 80 ng/kg p.o. daily
Days 7 to 11 6.05° 33.1° 8.4d 4.4 37.1 12.0l 45.2 52.6° 95.9 20.Od 37.2° 1071°
±0.12 ±2.0 ±1.0 ±1.1 ±3.4 ±1.3 ±3.1 ±1.9 ±3.2 ±1.5 ±2.2 ±43
(Day 11, (_58b) (+5P') (—5) (—3) (+65') (+60) (±59b) (+79c) (+131°) (+65b)
Group 2 (N = 5) Intact, P-restricted diet: Ca 3.0 mEq/kg as C1, KCI 3.0 and NaCI 3.0 mmoles/kg daily
Control 5.57 91.0 0.8 0.8 91.0 1.4 52.2 55.5 173.2 8.5 31.9 976
±0.06 ±2.5 ±0.2 ±0.2 ±2.5 ±0.3 ±2.8 ±1.1 ±3.7 ±0.6 ±1.4 ±24
l,25-(OH)2D3, 80 ng/kg p.o. daily
Days 7 to 11 5.42 60.0' 3.5' 0.5 62.8d 4.6' 51.0 56.0 168.8 31.9°' 25.1° 1038
±0.06 ±1.9 ±0.7 ±0.3 ±1.8 ±0.9 ±3.5 ±1.5 ±5.4 ±0.9 ±1.5 ±37
(Day 11, (—238°) (17) (1) (—222°) (20) (—11) (—3) (—10) (+ 183") (76°)
Group 3 (N = 4) Intact, CI2MDP pretreatment, P-restricted diet: Ca ± 3.0 mEq/kg as Cl, KCI 3.0 and NaCl 3.0 mmoles/kg daily
Control 5.53 90.6 0.2 0.2 90.6 0.2 53.7 56.0 169.0 8.4 39.3 1009
±0.04 ±2.0 ±0.1 ±0.1 ±2.1 ±0.1 ±2.1 ±2.0 ±4.5 ±0.6 ±1.1 ±42
l,25-(OH)2D3, 80 ng/kg p.o. daily
Days 7 to 11 5.48 73.6" 0.2 0.2 73.6" 0.2 48.0 56.6 168.5 30.2" 39.4 1058
±0.05 ±2.5 ±0.1 ±0.1 ±2.5 ±0.1 ±2.9 ±1.8 ÷5.2 ±1.5 ±0.9 ±33
(Day 11, (—102") (0) (—1) (—102") (—1) (—30) (—8) (55) (+ 198°) (+5)
Group 4 (N = 6) Intact, P-supplemented diet: Ca 3.0 mEq/kg as C1, Na 3.0 and K 3.0 mEq/kg as F', daily
Control 5.97 50.6 42.0 1.5 91.1 63.7 50.4 58.8 55.1 0.6 29.6 961
±0.94 ±1.8 ±1.3 ±0.3 ±2.7 ±1.7 ±1.9 ±1.2 ±2.8 ±0.2 ±1.5 ±38
1 ,25-(OH)2D3, 80 ng/kg p.o. daily
Days 7 to 11 5.68" 44.8" 50.4" 0.5° 94.7 68.2 45.9 58.0 46.1" 43d 31.9 980
±0.04 ±1.7 ±1.1 ±0.1 ±2.5 ±1.3 ±2.3 ±1.1 ±1.9 ±0.9 ±1.0 ±48
(Day 11, (—15) (+74°) (—12") (+70") (+38°) (—49) (—13) (—46) (+27) (+ 19)
Group 5 (N = 6) Intact, P-supplemented diet: Ca 3.0 mEq/kg as Cl, Na and K 3.0 mEq/kg as P daily
Control 5.87 58.9 46.0 1.4 103.6 67.1 47.4 59.7 58.9 0.3 28.7 978
±0.04 ±1.5 ±1.4 ±0.2 ±2.4 ±1.8 ±2.0 ±1.0 ±2.1 ±0.1 ±1.0 ±26
bPTH, 10/15 U/kg daily in 2 or 3 subcutaneous doses
High Ca' day 5.70 60.8 48.2 1.5 110.8 70.7 47.1 57.9 63.6 2.7" 25.8 1007
±0.18 ±8.0 ±10.4 ±0.8 ±14.5 ±7.8 ±4.0 ±4.1 ±8.1 ±0.7 ±4.8 ±93
Days 4 to 7 5.77 61.6 48.5 1.4 109.5 69.1 41.0 55.3 57.9 3.3" 29.4 977
±0.07 ±4.2 ±3.6 ±0.3 ±6.5 ±3.8 ±3.3 ±2.2 ±4.2 ±0.6 ±2.4 ±41
(Day 7, (17) (+6) (—1) (24) (—9) (_50b) (_4Øb) (—18) (+17") (+ 12)
1 ,25-(OH)2D3 dosage was 160 nglkg daily during days 1 to 3 in groups 1 to 4. High Ca ± day is defined as the first day of PTH administration in
which plasma total [Ca°] was at least 12.5 mg/l00 ml. In one dog of group 2 the value for day 11 was not available and thus, the value for day
10 was used in its place. Values are means ± sax; mean values were tested for significant differences from control and e footnoted by b, , and"
indicative of significance at the 0.05, 0.01, and 0.001 probability levels, respectively (Student's t test). All excretion values are normalized to 20 kg
body wt. Cumulative excretion is the accumulated sum of the daily differences from the mean control daily excretion value. Mean cumulative
excretion values were tested for significant differences from zero and are footnoted by b, , and "indicative of significance at the 0.05, 0.01, and
0.001 probability levels, respectively. Cumulative excretion values are denoted by parentheses. Abbreviation used is defined: TA, titratable acid
excretion.
the urinary anion gap. The urinary anion gap provides an index
of urinary excretion of anions other than bicarbonate, chloride,
and phosphate and therefore provides an index of the excretion
rates of the anions associated with the fixed acids of metabo-
lism, for example, sulfuric and organic acids [43]. The observed
reduction in the urinary anion gap of 7 mEq per 24 hours
accounts for only one fourth of the observed 28 mEq per 24
hours reduction in the net acid production rate as reflected in
the daily net acid excretion rate (group 2, Table 2). Based on
this consideration, we attributed the bulk of the apparent
reduction in net systemic acid load to an increased systemic
delivery of base equivalents, for example, hydroxyl, bicarbon-
ate, or organic anions metabolized to bicarbonate. It is not
known whether the effect of 1 ,25-(OH)2D3 to stimulate gastroin-
testinal calcium absorption [24] and bone release of calcium [25]
is accompanied by the translocation of base equivalents to the
extracellular fluid. It is possible that 1 ,25-(OH)2D3 might stimu-
late gastrointestinal absorption of ingested alkali (or anions
metabolizable to alkali).2 The possibility that the extrarenal
2A role for 1 ,25-(OH)2D3 to decrease the net systemic acid load by
increasing the steady-state gut absorption of alkali in groups I and 4 is
excluded by the absence of a prolonged reduction in net acid excretion
(reflecting the net systemic acid load) in these groups. This observation
also excludes a chronic role for alterations in gut transport to explain
the observed increments in the observed "set point" of renal regulation
of plasma bicarbonate concentration. Even if a steady-state increase in
gut alkali absorption of sufficient magnitude to substantially reduce net
acid excretion had occurred in groups Ito 4, the results of the studies in
group 7 indicate that this phenomenon per se is insufficient to result in
chronic metabolic alkalosis.
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Fig 2. Effect of PTH administration on
plasma and urinary acid-base and elec-
trolyte composition in intact dogs (group
5, N = 6). NAE represents urinary net
acid excretion; P, inorganic phosphate;
and TA, titratable acid excretion.
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source of alkali in group 2 is derived from bone or soft tissues is
supported by the precedent of increased bone release of alkali
in phosphate-restricted rats [14].
The possible role of 1 ,25-(OH)2D3-induced bone release of
alkali observed in the phosphorus deprived animals of group 2
was further elucidated in group 3 phosphorus-deprived dogs by
pretreatment with C12MDP, a potent inhibitor of bone mineral
(and hydroxyapatite crystal) dissolution/resorption [441.
C12MDP pretreatment significantly attenuated the effect of 1,25-
(OH)2D3 to both increase plasma calcium concentration and
decrease net acid excretion by comparison with the results in
group 2 (Tables I and 2). The observed attenuation of 1,25-
(OH)2D3-induced hyperbicarbonatemia by inhibition of bone
mineral resorption is thus consistent with the hypothesis that at
least a component of the chronic metabolic alkalosis induced by
l,25-(OH)2D3 administration is related to the bone release of
alkali salts of calcium.3
Because it is known that severe chronic phosphate depletion
in rats is associated with decreased rates of net acid excretion
(and presumably net systemic acid load [14]), the possibility
requires consideration that frank phosphate depletion was
induced by dietary phosphorus restriction and/or 1 ,25-(OH)2D3
administration in group 2, and thereby might account for the
3Because CI2MDP pretreatment in the phosphorus-restricted dogs of
group 3 also prevented the small but significant 1 ,25-(OH)2D3-induced
reduction in urinary anion gap observed in group 2, we cannot exclude
the possibility that a component of the attenuated decrease in net acid
excretion and attenuated alkalosis in group 3 is due to an attenuated
reduction in the production rate of the fixed acids of metabolism.
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decrease in net acid excretion and/or alkalosis observed in this
group. It is unlikely that phosphate depletion occurred of
sufficient magnitude to decrease the net systemic acid load
because the control (phosphorus restricted) net acid excretion
rate in group 2 was essentially identical to that in similarly
treated phosphorus-replete (group 4) animals. Because hypo-
phosphatemia was not present prior to or during 1 ,25-(OH)2D3
administration in the phosphorus-restricted dogs of group 2 and
the renal phosphorus losses during l,25-(OH)2D3 were small (20
mmoles), it is unlikely that the occurrence of phosphate deple-
tion (as distinct from hypophosphaturia) was a determinant of
the renal or systemic acid.base response in this group. Domin-
guez, Gray, and Lemann [45] have reported that prolonged
dietary phosphate deprivation in normal human subjects suffi-
cient to cause significantly negative phosphorus balance did not
result in significant alterations in the plasma bicarbonate con-
centration or net acid excretion. The reported observations of
decreased net acid excretion [14] and decreased renal bicarbon-
ate reabsorptive capacity [13, 14] in phosphate-depleted dogs
and rats have been in association with severe degrees of
depletion and marked hypophosphatemia. Moreover, based on
the measurements of plasma acid-base composition in phospho-
rus-depleted rats [14], if phosphorus depletion was a factor
altering the chronic renal regulation of the plasma bicarbonate
concentration in the phosphorus-restricted animals (group 2) of
the present studies, that alteration would result predictably in
metabolic acidosis rather than the observed metabolic alkalosis.
The results of studies in group 4 (phosphate-supplemented
dogs) establish that the alkalosis-producing effect of 1,25-
(OH)2D3 is not limited to phosphate-restricted and/or hypo-
phosphaturic states as in groups I and 2. Moreover, the studies
in phosphate-replete dogs reveal that the renal component of
metabolic alkalosis caused by 1 ,25-(OH)2D3 is accentuated in
the presence of an adequate urinary buffer for the titration of
secreted hydrogen ion. The cumulative increase in net acid
excretion was accounted for entirely by increased titratable
acid excretion which, in turn, was accounted for partially by an
increase in renal phosphate excretion and in part by a decrease
in urine pH. 1 ,25-(OH)2D3-induced increases in renal phosphate
clearance have been reported previously in hypoparathyroid
man [46]. Perpetuation of the alkalosis by the kidney is not
dependent on the presence of chloride or potassium depletion
because the urinary excretion rates of these ions approximated
control values throughout the period of 1 ,25-(OH)2D3 adminis-
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Fig 3. Effect of chronic substitution of
sodium bicarbonate (2.5 mmoles/kg
daily) for an equivalent amount of di-
etary sodium chloride on plasma and
urinary acid-base composition in intact
dogs (group 7, N = 4). TA represents
titratable acid excretion.
Fig 4. Effect of chronic intravenous cal-
cium infusion on plasma and urinary
acid-base and electrolyte composition in
a representative TPTX dog from group 8.
Control excretion values are depicted
within ovals. NAE represents urinary
net acid excretion; P1, inorganic phos-
phate; and TA, titratable acid excretion.
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tration and no consistent significant cumulative changes in
excretion of these ions occurred.4
Our studies of chronic PTH administration in group 5 indicate
that when chronic hypercalcemia is produced by an additional
agent capable of causing dissolution of calcium salts in bone,
both renal and extrarenal factors again operate to increase
plasma bicarbonate concentration and decrease blood acidity.
A significant decrease in the blood hydrogen ion concentration
and an increase in the plasma bicarbonate concentration were
observed in the absence of significant changes in net acid
excretion. As concluded for group 1, the increase in plasma
bicarbonate concentration was partially of an extrarenal origin
because net acid excretion did not increase, and in part of renal
origin because net acid excretion did not decrease. Failure to
observe a chronic phosphaturic effect of PTH in this group may
4The lack of a consistent change in sodium and chloride balance in
groups 1 to 4 makes an element of ECF volume contraction an unlikely
contributor to the observed increases in the plasma bicarbonate concen-
tration. However, the slight tendency to increases in urine flow rate and
plasma protein concentration as well as a tendency to weight loss make
this possibility difficult to exclude completely.
reflect a briefer duration of action of the hormone on renal
phosphate transport than on renal and systemic acid-base and
calcium homeostasis. Previous reports of prolonged PTH ad-
ministration to normal human subjects have not demonstrated a
consistent chronic phosphaturic effect of PTH [47, 48], and
numerous reports have been precedent to the delayed develop-
ment of resistance to other actions of PTH during its adminis-
tration [49—51].
Because PTH is known to stimulate the endogenous produc-
tion of l,25-(OH)2D3, the present studies do not exclude the
possibility that l,25-(OH)2D3 is the mediator of the renal and/or
extrarenal acid-base effects observed following PTH adminis-
tration [24]. Evidence against such a possibility, however, is
provided in the results of studies in which the effects of PTH on
bone salt dissolution were prevented by pretreatment with
CI2MDP. This interpretation, however, assumes that the domi-
nant effect of CI2MDP in renal and systemic acid-base equilibri-
um is an inhibition of the release of bone salts. This assumption
remains to be validated.
Hypoparathyroidism is a potential renal alkalosis-producing
factor by virtue of its reported effect to increase the renal
bicarbonate reabsorptive capacity as manifested in dogs during
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Table 3. Effect of chronic hypercalcemia induced by substitution of
intravenous Ca for Na on plasma and urinary acid-base
composition in TPTX dogs (group 8, N = 3)a
Control
Peak
hypercalcemia
Plasma
HCO, mEq/liter
H, nEq/!iter
PaCO2, mm Hg
Cl, mEqiliter
Na, mEqiliter
K, mEq/liter
Anion gap, mEqlliter
Ca, mg/IOO ml
P, mg/100 ml
20.1
39.5
32.5
115.4
145.9
4.0
14.4
8.3
6.1
l6.7
46.8
31.8
115.8
143.4
4.0
14.9
l8.1
5.7
Protein, g/100 ml
Creatinine, mg/100 ml
Wt, kg
Urine
pH
NH.t, mEq/24 hrs
TA, mEq/24 hrs
Net acid, mEq/24 hrs
K, mEq/24 hrs
P, mmoles/24 hrs
Anion gap, mEq/24 hrs
6.6 6.9b
±0.1
0.57 l.13c
14.7 13.1
6.49 5.68c
32.1 40.0
17.6 20.9
43.5 58.9'
49.5 45.2
39.1 31.8
34.0 31.2
a Peak hypercalcemia is defined as the 3-day period prior to and
including the day of maximal hypercalcemia. For each dog, the range of
values of plasma [Ca} did not exceed 3 mg/lOO ml during this 3-day
period. Anion gap in plasma is calculated as [Nat + K} — [C1 +
HCOfl and in urine as [NH + Na + K + Ca — [Cl + HCO +
HPO + H2POfl. Values are means SaM; mean values were tested
for significant differences from control and are footnoted by b and
indicative of significance at the 0.05 and 0.001 probability levels,
respectively (Student's t test). Abbreviations: H, hydrogen ion activi-
ty in arterial blood; PaCO2, CO2 tension in arterial blood; TA, titratable
acid excretion.
acute bicarbonate infusion [41. However, the aparathyroid state
induced by the TPTX model in groups 1, 8, and 9 was not
associated with metabolic alkalosis during the prehypercalce-
mic control period. Furthermore, the endogenous suppression
of PTH as a contributory factor to the acid-base effects of the
experimental maneuvers in these groups is precluded by the
absence of a potential for PTH secretion.
The results of groups 8 and 9 studies in which sustained
hypercalcemia was produced by a progressive increase in the
rate of calcium infusion coupled with a progressive decrease in
Fig 5. Effect of chronic increases in plasma total calcium concentration
(mg/100 ml) on plasma bicarbonate concentration (mEqiliter). The
values depicted are expressed as differences ('.) from the control period
mean for each dog. Administration of I ,25-(OH)2D or PTH refers to
groups 1, 2, 4, and 5 whereas the administration of intravenous calcium
salts refers to groups 8 and 9.
the rate of sodium infusion to TPTX dogs, establish that the
character and direction of the renal and systemic acid-base
response to chronic hypercalcemia is critically dependent on
whether or not the source of increased calcium in ECF is
endogenous (bone, soft tissue) or exogenous (infused) in origin.
When hypercalcemia is produced from bone (or possibly gut),
the associated release of alkali salts leads to an extrarenal
increase in the plasma bicarbonate concentration. The renal
response to hypercalcemia and/or hypercalcemia-producing
agents subsequently serves to sustain the increase in plasma
bicarbonate concentration and in some cases clearly partici-
pates in the generation of metabolic alkalosis (group 4). When
chronic hypercalcemia is produced by an intravenous infusion
of alkali-free calcium salts, hypercalcemia induced an extrare-
nal decrease in the plasma bicarbonate concentration associat-
ed with a directionally appropriate renal response, that is,
increased net acid excretion.
Taken together, the results of the present studies thus suggest
that the movement of calcium to or from ECF and bone (and/or
soft tissue) in response to hypercalcemia-producing agents is
accompanied by a directionally similar movement of base
equivalents which results in either metabolic acidosis or alkalo-
sis depending on the direction of calcium net movement: (1)
Calcium infusion —+ base deposition in bone/soft tissue —
metabolic acidosis; (2) l,25-(OH)2D3 or PTH administration —
base release from bone — metabolic alkalosis. Moreover,
chronic 1 ,25-(OH)2D3 or PTH administration increases the set
point at which the plasma bicarbonate concentration is regulat-
ed by the kidney and thereby causes metabolic alkalosis to
persist.
Acknowledgments
We thank Russell P. White, Hardin Jones, Michael Daily, and Jane
Heaney for technical assistance, and Lois Deenihan for typing the
manuscript. These experiments were supported by grant SF76-63,
Public Health Service, Central Clinical Investigation Committee, and
National Institutes of Health grants RR-00079, AM-21605, and AM-
28643.
Plasma
[Bicarbonate]
—4
+ 1, 25-(OH)2D3
x PTH
Plasma
Total [Calcium]
A ,AA A +20
A *
—8
• Calcium/sodium chloride
* Calcium/sodium thiosulfate
Chronic acid-base effects of hypercalcemia 457
Reprint requests to Dr. Henry N. Hulter, Chief, Renal Service
(luG), Veterans Administration Medical Center, Gainesville, Florida
32602, USA
References
1. WALLACH S, CARTER AC: Metabolic and renal effects of acute
hypercalcemia in dogs. Am J Physiol 200:359—366, 1961
2. ARDAILLOU R, AMIEL C, LECESTRE M, RICHET G: Acidification de
l'urine apres injection intraveineuse de sets de calcium chez
l'homme II. Effets compares du gluconate et du chlorure de
calcium. Rev Fr Etudes Clin Biol 8:541—552, 1963
3. DUMAS R, REMEDIANI F, BONNET H, JEAN R: Trouble de Ia
regulation renale acido-basique au cours de l'hypercalcemie aigue.
Arch Fr Pediatr 27:967—977, 1970
4. CRUMB CK, MARTINEZ-MALDONADO M, EKNOYAN G, SUKI WN:
Effects of volume expansion, purified parathyroid extract and
calcium on renal bicarbonate absorption in the dog. J Clin In vest
54:1287—1294, 1974
5. FERRIS T, KASHGARIAN M, LEvITIN H, BRANDT 1, EPSTEIN FH:
Renal tubular acidosis and renal potassium wasting acquired as a
result of hypercalcemic nephropathy. N EngI J Med 265:924—928,
1961
6. HEINEMANN HO: Reversible defect in renal ammonium excretion
in patients with hypercalcemia. Metabolism 12:792—803, 1963
7. HEINEMANN HO: Metabolic alkalosis in patients with hypercalce-
mia. Metabolism 14:1137—1152, 1965
8. WILLs MR: Value of plasma chloride concentration and acid-base
status in the differential diagnosis of hyperparathyroidism from
other causes of hypercalcemia. J Clin Pathol 24:219—227, 1971
9. PERAINO RA, GHAFARY E, ROUSE D, STINEBAUGH BJ, SUKI WN:
Effect of 25-hydroxycholecalciferol on renal handling of sodium,
calcium, and phosphate during bicarbonate infusion. Mineral Elec-
trolyte Metab 1:321—329, 1978
10. SIEGFRIED D, KUMAR R, ARRUDA J, KURTZMAN N: Influence of
vitamin D on bicarbonate reabsorption, in Phosphate Metabolism,
edited by MASSRY SG, RITZ E, New York and London, Plenum
Press, 1978, pp. 395—404
II. VERNER JV JR, ENGEL FL, MCPHERSON HT: Vitamin D intoxica-
tion: Report of two cases treated with cortisone. Ann mt Med
48:765—773, 1958
12. FERRIS TF, LEvITIN H, PHILLIPS ET, EPSTEIN FH: Renal potassi-
um-wasting induced by vitamin D. J Clin In vest 41:1222—1229, 1962
13. GOLD LW, MASSRY SH, ARIEFF Al, COBURN JW: Renal bicarbon-
ate wasting during phosphate depletion. J Clin Invest 52:2556—2562,
1973
14. EMMETT M, GOLDFARB S, AGUS ZS, NARINS RG: The pathophysi-
ology of acid-base changes in chronically phosphate-depleted rats.
J Clin Invest 59:291—298, 1977
15. LAVENDER AR, PULLMAN TN: Changes in inorganic phosphate
excretion induced by renal arterial infusion of calcium. Am J
Physiol 205:1025—1032, 1963
16. VAVATSI-MANOS 0, PREUSS HG: The effects of high calcium
concentrations on renal ammoniagenesis by rat kidney slices.
Nephron 17:474—482, 1976
17. ARRUDA JAL: Calcium inhibits urinary acidification: Effect of the
ionophore A23 187 on the turtle bladder. Pfluegers Arch 381:107—
111, 1979
18. FRALEY DS, ADLER 5: An extrarenal role for parathyroid hormone
in the disposal of acute acid loads in rats and dogs. J Clin Invest
63:985—997, 1979
19. HELLMANN DE, Au WYW, BARTTER FC: Evidence for a direct
effect of parathyroid hormone on urinary acidification. Am J
Physiol 209:643—650, 1965
20. KARLINSKY ML, SAGERDS, KURTZMAN NA, PILLAY VKG: Effect
of parathormone and cyclic adenosine monophosphate on renal
bicarbonate reabsorption. Am J Physiol 227:1226—1231, 1974
21. ARRUDA JAL, NASCIMENTO L, WESTENFELDER C, KURTZMAN
NA: Effect of parathyroid hormone on urinary acidification. Am J
Physiol 232:F429—F433, 1977
22. IINO Y, BURG MB: Effect of parathyroid hormone on bicarbonate
absorption by proximal tubules in vitro. Am J Physiol 236:F387—
F391, 1979
23. ARRUDA JAL, KURTZMAN NA: Hyperparathyroidism and metabol-
ic acidosis. A complex interaction of multiple factors. Nephron
26:1—6, 1980
24. DELucA HF: Vitamin D metabolism and function. Arch Intern Med
138:836—847, 1978
25. TANAKA Y, DELUCA HF: Bone mineral mobilization activity of
1 ,25-dihydroxycholecalciferol, a metabolite of vitamin D. Arch
Biochem Biophys 146:574—578, 1971
26. HULTER HN, ILNICKI LP, HARBOTTLE JA, SEBASTIAN A: Impaired
renal H secretion and NH3 production in mineralocorticoid defi-
cient glucocorticoid-replete dogs. Am J Physiol 232:Fl36—F146,
1977
27. BELSHAW BE, RIJNBERK AD: Hypothyroidism, in Current Veteri-
nary Therapy VI, edited by KIRK RW, Philadelphia, W.B. Saunders
Co., 1977, pp. 1017—1019
28. RUSSELL RGG, FLEISCH H: Pyrophosphate and diphosphonates in
skeletal metabolism. Clin Orthop 108:241—263, 1975
29. HULTER HN, LICHT JH, GLYNN RD, SEBASTIAN A: Renal acidosis
in mineralocorticoid deficiency is not dependent on NaCI depletion
or hyperkalemia. Am J Physiol 236:F283—F294, 1979
30. DEAN JA, ed: Lange's Handbook of Chemistry (12th ed), New
York, McGraw-Hill, 1979, pp. 5—17
31. KLEIN B, KAUFMAN JH, MORGANSTERN 5: Determination of
serum calcium by automated atomic absorption spectroscopy. Clin
Chem 13:388—396, 1967
32. KLEIN B, KAUFMAN JH, OKLANDER M: Automated atomic absorp-
tion spectrophotometry. III. Calcium in urine and spinal fluid. Clin
Chem 13:797—805, 1967
33. ALEXANDER R: Evaluation of an automatic calcium titrator. Clin
Chem 17:1171—1175, 1971
34. WYBENGA DR, IBBOTT FA, CANNON DC: Determination of ionized
calcium in serum that has been exposed to air. Clin Chem 22:1009—
1011, 1976
35. SNEDICOR GW, COCHRAN WG: StatisticalMethods (6th ed). Ames,
Iowa, Iowa State University Press, 1967
36. RECKER RR, HASSING GS, LAU JR, SAVILLE PD: The hyperphos-
phatemic effect of disodium ethane-l-hydroxyl-I, 1-diphosphonate
(EHDP): Renal handling of phosphorus and the renal response to
parathyroid hormone. J Lab Clin Med 81:258—266, 1973
37. PARFITT AM: The actions of parathyroid hormone on bone: Rela-
tion to bone remodeling and turnover, calcium homeostasis, and
metabolic bone diseases. Part LI of IV Parts: PTH and bone cells:
Bone turnover and plasma calcium regulation. Metabolism 25:909—
955, 1976
38. RELMAN AS, LENNON EJ, LEMANN J JR: Endogenous production
of fixed acid and the measurement of the net balance of acid in
normal subjects. J Clin Invest 40:1621—1630, 1961
39. LEMANN J JR, LENNON EJ, GOODMAN AD, LITZOW JR, RELMAN
AS: The net balance of acid in subjects given large loads of acid or
alkali. J Clin Invest 44:507—517, 1965
40. HULTER HN, SEBASTIAN A, SIGALA JF, LICHT JH, GLYNN RD,
SCHAMBELAN M, BIGLIERI EG: Pathogenesis of renal hyperchlore-
mic acidosis resulting from dietary potassium restriction in the dog:
Role of aldosterone. Am J Physiol 238:F79—F9l, 1980
41. TANNEN RL: The effect of uncomplicated potassium depletion on
urine acidification. J Clin Invest 49:813—827, 1970
42. SEBASTIAN A, SCHAMBELAN M, LINDENFELD S, MORRIS RC JR:
Amelioration of metabolic acidosis with fludrocortisone therapy in
hyporeninemic hypoaldosteronism. N EngI J Med 297:576—583,
1977
43. HULTER HN, LICHT JH, BONNER EL JR, GLYNN RD, SEBASTIAN
A: Effects of glucocorticoid steroids on renal and systemic acid-
base metabolism. Am J Physiol 239:F30—F43, 1980
44. RUSSELL RGG, MUHLBAUER RC, BI5Az 5, WILLIAMS DA,
FLEISCH H: The influence of pyrophosphate, condensed phos-
phates, phosphonates, and other phosphate compounds on the
dissolution of hydroxyapatite in vitro and on bone resorption
induced by parathyroid hormone in tissue culture and in thyropar-
athyroidectomized rats. Calcif Tissue Res 6:183—196, 1970
45. DOMINGUEZ JH, GRAY RW, LEMANN J JR: Dietary phosphate
deprivation in women and men: Effects on mineral and acid
balances, parathyroid hormone, and the metabolism of 25-OH-
vitamin D. J Clin Endocrinol Metab 43:1056—1068, 1976
458 Hulter et a!
46. ARGEMI B, VAGNEUR JP, CoDAccioNi JL, SIM0NIN R: Hypopara-
thyroidism: Long-term treatment with dihydrotachysterol, 25-h y-
droxyvitamin D3 and 1 ,25-dihydroxyvitamin D3, in Vitamin D Basic
Research and Its Clinical Application, edited by NORMAN AW,
SCHAEFER K, HERRATH DV, GRIGOLLET H-G, COBURN JW,
DELUCA HF, MAUER EB, SUDA T. New York, W. DeGruyter,
1979, pp. 1057—1060
47. DANCASTER CP, SCHENDEL HE, JACKSON WPU: Response to
prolonged intramuscular administration of parathyroid hormone in
the normal human subject. Clin Sci Mo! Med 19:563—571, 1960
48. ALBRIGHT F, BAUER W, ROPES M, AUB JC: Studies of calcium and
phosphorus metabolism. IV. The effect of the parathyroid hor-
mone. J Clin Invest 7:139—181, 1929
49. WONG GL: Induction of metabolic changes and down regulation of
bovine parathyroid hormone-responsive adenylate cyclase are dis-
sociable in isolated osteoclastic and osteoblastic bone cells. J Biol
Chem 254:34—37, 1979
50. OBIE iF, COOPER CW: Loss of calcemic effects of calcitonin and
parathyroid hormone infused continuously into rats using the Alzet
osmotic minipump. J Pharmacol Exp Ther 209:422—428, 1979
51. TOMLIN50N S, HENDY GN, PEMBERTON DM, O'RIORDAN JLH:
Reversible resistance to the renal action of parathyroid hormone in
man. Clin Sci Mol Med 5 1:59—69, 1976
